4basebio PLC Overview
Pro stress-test →4basebio is a Cambridge-based biotechnology company pioneering synthetic DNA production through its proprietary enzymatic DNA synthesis platform, producing GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability. The company offers application-specific DNA constructs tailored for gene therapies, genome editing, mRNA production, and DNA vaccines.
Strategic Profile
Pro stress-test →Following FDA IND approval, a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA product developed using 4basebio's proprietary opDNA® template. Since completing a £40 million investment in November 2024, 4basebio achieved MHRA GMP certification in April 2025 for manufacture and supply of synthetic DNA for clinical use.
Competitive Landscape
Pro stress-test →4basebio competes in the synthetic DNA and advanced therapeutics sector, addressing plasmid-based production limitations with enzymatic synthesis. Main competitors include Ginkgo Bioworks, Synthego, and other synthetic biology platforms, differentiated by GMP-grade manufacturing capability and pharma validation.
Industry Context
4basebio PLC operates in Synthetic Biology / Advanced Therapeutics Manufacturing.
Key facts
Founded: 2008 · Headquarters: Cambridge, UK · Employees: 101 · Market cap: £85.17m